Amplitude Healthcare Acquisition Corporation
AMHCW
NASDAQ Capital Market1.57
USD
+0.05
- -
CIK
0001788028
Return %
Stock
S&P500
1Y
- -
26.84
3Y
- -
77.03
5Y
- -
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- None
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- DE United States of America
- IPO Date
- Jan 10, 2020
- CIK
- 0001788028
- Similar Companies
- Business
- Amplitude Healthcare Acquisition Corporation is a special purpose acquisition company (SPAC) incorporated in 2019 and headquartered in New York, New York. The company focuses on effecting mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or related business combinations primarily within the life sciences and pharmaceutical services sectors in the United States and Europe. Its principal recent activity includes a business combination with Jasper Therapeutics, Inc., a biotechnology company dedicated to hematopoietic cell transplant therapies. This transaction, completed in 2021, created a publicly traded biotechnology entity focused on enabling cures through hematopoietic stem cell therapy and involved a reverse merger with Amplitude Healthcare Acquisition Corporation, backed by a committed PIPE financing of approximately $100 million led by prominent institutional investors. Through this combination, Amplitude Healthcare Acquisition Corporation expanded its product and service portfolio to include Jasper Therapeutics’ advanced clinical-stage anti-CD117 antibody transplant conditioning agent and engineered hematopoietic stem cell platform, which target the expansion of hematopoietic stem cell therapy applications. The company’s operations now encompass research and development, clinical therapeutic programs, and biotechnology manufacturing related to cell transplant therapies. Recent strategic developments include the completion of the combination with Jasper Therapeutics and securing substantial financing commitments to advance drug development. The company’s strategic focus is on expanding its pipeline and geographic operations in the United States and Europe, with significant institutional investor participation supporting growth initiatives. Amplitude Healthcare Acquisition Corporation intends to leverage this foundation to accelerate innovation in hematopoietic cell therapies and expand patient access to potentially curative treatments in the biotechnology sector.